Myasthenia Gravis Clinical Trials in Houston, Texas
10 recruitingHouston, Texas
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals180 enrolled99 locationsNCT06744920
Recruiting
Phase 1Phase 2
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Novartis Pharmaceuticals15 enrolled10 locationsNCT06704269
Recruiting
Phase 2Phase 3
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis
Kyverna Therapeutics66 enrolled15 locationsNCT06193889
Recruiting
Phase 3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled110 locationsNCT06517758
Recruiting
Phase 3
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Generalized Myasthenia Gravis
Vor Biopharma180 enrolled84 locationsNCT06456580
Recruiting
Phase 1
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Myasthenia GravisMuscle WeaknessAutoimmune Diseases+4 more
Arcellx, Inc.30 enrolled13 locationsNCT06626919
Recruiting
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.500 enrolled51 locationsNCT04202341
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Myasthenia Gravis
ImmunAbs Inc.96 enrolled25 locationsNCT07250750
Recruiting
Vitaccess Real MG Registry
Myasthenia Gravis
Vitaccess Ltd600 enrolled8 locationsNCT06064461
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia Gravis+1 more
COUR Pharmaceutical Development Company, Inc.54 enrolled17 locationsNCT06106672